Skip to main content

Table 4 The relationship between clinico-pathological characteristics of patients with ER positive primary operable invasive ductal breast cancer and cancer- specific survival

From: The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer

 

    Univariate survival analysis

    Multivariate survival analysis

 

     Cancer-specific survival

     Cancer-specific survival

 

   Hazard ratio

P-value

   Hazard ratio

P-value

 

    (95% CI)

 

    (95% CI)

 

Age (<50/>50 years)

1.82 (0.77-4.33)

0.173

  

Size (≤20/21-50/>50 mm)

2.04 (1.20-3.49)

0.009

 

0.116

Grade (I/II/III)

1.71 (1.09-2.68)

0.019

 

0.342

Involved lymph node (0/1-3/>3)

2.26 (1.54-3.32)

<0.001

2.11 (1.40-3.20)

<0.001

Progesterone -receptor status (PR-/PR+)

0.72 (0.38-1.37)

0.316

  

HER-2 status (HER-2 -/HER-2+)

2.17 (0.96-4.88)

0.062

 

0.109

Ki-67 status (Low Ki-67/High Ki-67)

3.71 (1.98-6.96)

<0.001

3.62 (1.88-7.00)

<0.001

LVI (Absent/Present)

2.98 (1.62-5.47)

<0.001

2.36 (1.22-4.58)

0.011

MVD (CD34+) (tertiles 1, 2, 3)

1.41 (0.95-2.08)

0.087

 

0.667

Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radiotherapy)

1.75 (0.90-3.43)

0.100

  

Systemic treatment (ER-based treatment) (hormonal/hormonal + chemotherapy/chemotherapy/none)

1.45 (1.03-2.05)

0.033

 

0.481